For example, in Theiler’s virus infection of the CNS, which induces an immune-mediated demyelinating disease resembling multiple sclerosis, synthetic CBR agonists WIN 55,212–2 (nonselective CB1/CB2 agonist), ACEA (selectivity over CB1R), and JWH-015 (selectivity over CB2R) improved motor functions, reduced microglial activation and number of CD4+ infiltrating T-cells in the spinal cord, and promoted remyelination in infected animals, clearly suggesting the therapeutic potential of targeting ECS in multiple sclerosis [264]. This evidence concerns the gene CNR1 and demyelinating disease.